Showing results (31-40 of 61) with videos related to
Sort By:
Pageof 7
The Journal of Thoracic and Cardiovascular Surgery|January 6, 2005
Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has comeMalcolm V Brock, Craig M Hooker, James E Syphard, et al.RMD Open|November 1, 2023
Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseasesPaola Ghanem, Joseph C Murray, Kristen A Marrone, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerScott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2017
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateNasser Hanna, David Johnson, Sarah Temin, et al.BMJ Open|January 26, 2022
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trialPeey Sei Kok, Patrick M Forde, Brett Hughes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancerChristopher G Azzoli, Sherman Baker, Sarah Temin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2011
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung CancerChristopher G Azzoli, Sarah Temin, Timothy Aliff, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2025
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung CancerMark M Awad, Patrick M Forde, Nicolas Girard, et al.European Journal of Cancer (Oxford, England : 1990)|June 14, 2019
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trialMartin Reck, Michael Schenker, Ki Hyeong Lee, et al.Journal of the National Cancer Institute|June 7, 2007
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional studyFumiko Taguchi, Benjamin Solomon, Vanesa Gregorc, et al.Pageof 7